Our work focuses on developing new biomarkers for FTD. We hope that these will be used in clinical trials both to understand when to start treatment and also to work out whether drugs are working or not. We investigate multiple different types of biomarkers including cognition, MR and PET imaging, and blood and spinal fluid measures.
See Jonathan Rohrer describe the work of the team:
Our work also aims to support patients with FTD and their family members throughout the lifetime of the disease and into trials.